ARK Genomic Revolution ETF ARKG

Morningstar Medalist Rating

Morningstar’s Analysis ARKG

Will ARKG outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ARK Genomic Revolution ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings58.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Tempus AI Inc Class A common stock

10.21198M
Healthcare

10x Genomics Inc Ordinary Shares - Class A

7.95154M
Healthcare

Twist Bioscience Corp

7.58147M
Healthcare

CRISPR Therapeutics AG

5.19100M
Healthcare

Guardant Health Inc

5.1099M
Healthcare

Eli Lilly and Co

4.8293M
Healthcare

Absci Corp

4.7592M
Healthcare

Natera Inc

4.6790M
Healthcare

Illumina Inc

4.4887M
Healthcare

Beam Therapeutics Inc

3.8073M
Healthcare

Sponsor Center